About this trial
Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies.
This is a single-center prospective observational study. The investigators aim to: (1) track critically ill patients undergoing clinically indicated EEG monitoring and seizure management to identify risk factors for electrographic seizures, (2) create prediction models guiding EEG monitoring resources to the patients at highest risk for seizures, and (3) evaluate our current management strategy in terms of safety.
Eligibility criteria
Qualifiers
Care in the Children's Hospital of Philadelphia Pediatric ICU.
Clinically indicated continuous EEG monitoring.
Age > 1 month to 18 years.
Disqualifiers
Admitted for Phase 2 (intracranial) EEG monitoring.
Intensivist expects to discontinue technological support in the next two days given underlying medical or neurological problems.
Trial design
Treatments tested in this trial
- Clinically indicated EEG monitoring.
Treatment groups
Sponsors and collaborators
Children's Hospital of Philadelphia
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator